PDF herunterladen
CC BY-NC-ND 4.0 · J Lab Physicians 2023; 15(03): 344-353
DOI: 10.1055/s-0042-1760668
Original Article

A Rapid Method for Determination of Serum Methotrexate Using Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry and Its Application in Therapeutic Drug Monitoring

Naresh Kumar Tripathy
1   Department of Haematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Shravan Kumar Mishra
2   Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Gopi Nathan 
1   Department of Haematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Shreya Srivastava
2   Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Anshul Gupta
1   Department of Haematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Raghavendra Lingaiah
2   Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objectives Methotrexate (MTX) has anticancer therapeutic potential with multiple doses-related adverse effects and toxicities. Immunoassays for therapeutic monitoring of serum MTX have their own limitations. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) is considered as the reference method; however, commercially availability of them is limited. We aimed to adapt/develop an in-house LC-MS/MS method for therapeutic monitoring of serum MTX.

Materials and Methods Serum protein precipitation was performed using acetonitrile–water containing 250 μM solution of aminoacetophenone as internal standard (IS). Chromatographic separation was achieved on a C18 column with mobile phase of 0.1% solution of formic acid (solvent A) and acetonitrile (solvent B) at a flow rate of 0.4 mL/min. MS was performed under positive ion mode with mass transition for MTX and IS as m/z 455.1→308.1 and 136.2→94.1, respectively. The method was validated by following Bioanalytical Method Validation Guidance for Industry, 2018 and applied on leukemia patients' samples on MTX therapy.

Results The correlation coefficient of eight serially diluted calibration standards of 0.09 to 12.5 μM was >0.99 and had linearity with > 95% precision and accuracy at analytical quality control levels. The lower limit of MTX quantification achieved was 0.09 μM with good intensity and sharp peak as compared with blank sample. The total run time of the assay was 5 minutes. The serum MTX levels obtained by this method in leukemia patients exhibited clinical correlation and an excellent agreement with commercial immunoassay used in parallel.

Conclusion We were able to develop a rapid, sensitive, and cost-effective LC-MS/MS method suitable for therapeutic drug monitoring of MTX in routine clinical diagnostic laboratories.

Keywords

methotrexate - therapeutic drug monitoring - cancer - liquid chromatography - tandem mass - spectrometry


Publikationsverlauf

Artikel online veröffentlicht:
18. Januar 2023

© 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zarou MM, Vazquez A, Vignir Helgason G. Folate metabolism: a re-emerging therapeutic target in haematological cancers. Leukemia 2021; 35 (06) 1539-1551
    CrossrefPubMedSuche in Google Scholar
  • 2 Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994; 34: 397-419
    CrossrefPubMedSuche in Google Scholar
  • 3 Yu J, Du H, Ye X, Zhang L, Xiao H. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Sci Rep 2021; 11 (01) 2125
    CrossrefPubMedSuche in Google Scholar
  • 4 Gong F, Meng Q, Liu C, Zhao Y. Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia. Oncol Lett 2019; 17 (05) 4423-4428
    PubMedSuche in Google Scholar
  • 5 Sakura T, Hayakawa F, Sugiura I. et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG. Leukemia 2018; 32 (03) 626-632
    CrossrefPubMedSuche in Google Scholar
  • 6 Gros L, Roldán A, Cabero-Martínez A. et al. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: a Delphi study. J Oncol Pharm Pract 2022; 10 781552221079568
    Suche in Google Scholar
  • 7 Yang Y, Wang X, Tian J, Wang Z. Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate. Med Sci Monit 2018; 24: 7719-7726
    CrossrefPubMedSuche in Google Scholar
  • 8 Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016; 21 (12) 1471-1482
    CrossrefPubMedSuche in Google Scholar
  • 9 Abe K, Maeda-Minami A, Ishizu T. et al. Risk factors for hepatic toxicity of high-dose methotrexate in patients with osteosarcoma. Anticancer Res 2022; 42 (02) 1043-1050
    CrossrefPubMedSuche in Google Scholar
  • 10 Kubota M, Nakata R, Adachi S. et al. Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity. Leuk Lymphoma 2014; 55 (07) 1591-1595
    CrossrefPubMedSuche in Google Scholar
  • 11 Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014; 15 (10) 517-524
    CrossrefPubMedSuche in Google Scholar
  • 12 Daetwyler E, Bargetzi M, Otth M, Scheinemann K. Late effects of high-dose methotrexate treatment in childhood cancer survivors-a systematic review. BMC Cancer 2022; 22 (01) 267
    CrossrefPubMedSuche in Google Scholar
  • 13 Chen YC, Sheen JM, Wang SC. et al. Methotrexate neurotoxicity is related to epigenetic modification of the myelination process. Int J Mol Sci 2021; 22 (13) 6718
    CrossrefPubMedSuche in Google Scholar
  • 14 Cohen IJ. Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. Cancer Chemother Pharmacol 2017; 79 (06) 1057-1065
    CrossrefPubMedSuche in Google Scholar
  • 15 Baughman RP, Cremers JP, Harmon M, Lower EE, Drent M. Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (03) e2020001
    PubMedSuche in Google Scholar
  • 16 Mandal P, Samaddar S, Chandra J, Parakh N, Goel M. Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia/lymphoma: a retrospective study. Indian J Hematol Blood Transfus 2020; 36 (03) 498-504
    CrossrefPubMedSuche in Google Scholar
  • 17 Kremer JM. Methotrexate pulmonary toxicity: deep inspiration. Arthritis Rheumatol 2020; 72 (12) 1959-1962
    CrossrefPubMedSuche in Google Scholar
  • 18 D'Elia T. Methotrexate-induced pneumonitis: heterogeneity of bronchoalveolar lavage and differences between cancer and rheumatoid arthritis. Inflamm Allergy Drug Targets 2014; 13 (01) 25-33
    CrossrefPubMedSuche in Google Scholar
  • 19 Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005; 4 (04) 723-730
    CrossrefPubMedSuche in Google Scholar
  • 20 Shi X, Gao H, Li Z. et al. Modified enzyme multiplied immunoassay technique of methotrexate assay to improve sensitivity and reduce cost. BMC Pharmacol Toxicol 2019; 20 (01) 3
    CrossrefPubMedSuche in Google Scholar
  • 21 Karami F, Ranjbar S, Ghasemi Y, Negahdaripour M. Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples. J Pharm Anal 2019; 9 (06) 373-391
    CrossrefPubMedSuche in Google Scholar
  • 22 Albertioni F, Rask C, Eksborg S. et al. Evaluation of clinical assays for measuring high-dose methotrexate in plasma. Clin Chem 1996; 42 (01) 39-44
    CrossrefPubMedSuche in Google Scholar
  • 23 Mulder MB, Huisman R, Engels FK, Sluis IMV, Koch BCP. Therapeutic drug monitoring of methotrexate in plasma using ultra high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: necessary after administration of glucarpidase in methotrexate intoxications. Ther Drug Monit 2018; 40 (04) 383-385
    CrossrefPubMedSuche in Google Scholar
  • 24 Oudart JB, Marquet B, Feliu C, Gozalo C, Djerada Z, Millart H. Analytical interference in the therapeutic drug monitoring of methotrexate. Ann Biol Clin (Paris) 2016; 74 (03) 333-337
    PubMedSuche in Google Scholar
  • 25 Young A, Beriault D, Jung B. et al. DAMPAned methotrexate: a case report and review of the management of acute methotrexate toxicity. Can J Kidney Health Dis 2019; 6: 20 54358119895078
    CrossrefPubMedSuche in Google Scholar
  • 26 Zhang Y, Sun L, Zhao L, Wang X, Zhao Z, Mei S. Methotrexate polyglutamates analysis by chromatography methods in biological matrices: a review. Anal Sci 2021; 37 (12) 1655-1664
    CrossrefPubMedSuche in Google Scholar
  • 27 Wu D, Wang Y, Sun Y, Ouyang N, Qian J. A simple, rapid and reliable liquid chromatography-mass spectrometry method for determination of methotrexate in human plasma and its application to therapeutic drug monitoring. Biomed Chromatogr 2015; 29 (08) 1197-1202
    CrossrefPubMedSuche in Google Scholar
  • 28 United States Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. 2018 . Accessed at: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
    PubMedSuche in Google Scholar
  • 29 McTaggart MP, Keevil BG. A rapid LC-MS/MS assay for the measurement of serum methotrexate in patients who have received high doses for chemotherapy. Ann Clin Biochem 2021; 58 (06) 599-604
    CrossrefPubMedSuche in Google Scholar